Natco Pharma Ltd (NSE: NATCOPHARM, BSE: 524816) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹15,869 Cr, it ranks #436 by market cap among the 6,197 Indian listed companies on FinBizNet, and #18 of 86 in Medicinal Chemicals and Botanical Products. At ₹808.00 (as of 16 Nov 2026), the share price is 34.1% below its 52-week high of ₹1,226.80 and 4.4% above its 52-week low of ₹773.60. The share price is up 1.0% over one year and down 14.8% over three months.
| Current Price | ₹808.00 |
|---|---|
| Market Cap | ₹15,869 Cr |
| NSE Symbol | NATCOPHARM |
| BSE Code | 524816 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 10.2 |
| Return on Equity | 16.85% |
| Return on Assets | 7.98% |
| 52-Week Range | ₹773.60 – ₹1,226.80 |
| 1-Year Price Change | +1.0% |
| 3-Month Price Change | -14.8% |
| Beta (1Y) | 0.17 |
| Dividend Yield | 0.56% |
| Headquarters | Hyderabad, Telangana |
| Website | www.natcopharma.co.in |
| Revenue | ₹967 Cr |
|---|---|
| Net Profit | ₹203 Cr |
| Net Margin | 20.9% |
| EPS (Basic) | ₹11.31 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Natco Pharma Ltd reported revenue of ₹967 Cr in Q2 FY27, down 29.0% from ₹1,363 Cr in Q2 FY26 and up 31.6% from ₹735 Cr in Q1 FY27. It posted a net profit of ₹203 Cr for the quarter, against a net profit of ₹518 Cr in Q2 FY26 (down 60.9%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹647 Cr (Q3 FY26) to ₹1,363 Cr (Q2 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹967 Cr | ₹203 Cr | 20.9% |
| Q1 FY27 | ₹735 Cr | ₹207 Cr | 28.1% |
| Q4 FY26 | ₹739 Cr | ₹269 Cr | 36.4% |
| Q3 FY26 | ₹647 Cr | ₹151 Cr | 23.4% |
| Q2 FY26 | ₹1,363 Cr | ₹518 Cr | 38.0% |
| Q1 FY26 | ₹1,329 Cr | ₹480 Cr | 36.1% |
| Q4 FY25 | ₹1,221 Cr | ₹406 Cr | 33.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 46.22% of Natco Pharma Ltd's shares as of Oct 2026, against 49.48% in Dec 2025 (−3.26 percentage points). Delivery averaged 52.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of i
1. Pharmaceuticals-This segment develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients. 2. Agro Chemicals-This segment offers agro chemicals. 3. Unallocated-0 4. Segment Adjustment-0
1. Pharmaceuticals-96.6% 2. Agro Chemicals-3.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Natco Pharma Ltd | ₹15,869 Cr | 10.2 | 16.85% | ₹967 Cr | +1.0% |
Listed by market capitalisation. Ratios are shown for context only.
Natco Pharma Ltd is trading at ₹808.00, with a market capitalisation of ₹15,869 Cr.
Natco Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Natco Pharma Ltd has a P/E of 10.2 and a return on equity of 16.85%.
Natco Pharma Ltd is listed on the NSE under the symbol NATCOPHARM and on the BSE under the scrip code 524816.
Natco Pharma Ltd's share price is up 1.0% over one year and down 14.8% over three months. Its 52-week range is ₹773.60 to ₹1,226.80.
In Q2 FY27, Natco Pharma Ltd reported revenue of ₹967 Cr and net profit of ₹203 Cr, with basic EPS of ₹11.31 (consolidated, parsed from the company's exchange filing).
Natco Pharma Ltd reported revenue of ₹967 Cr in Q2 FY27, down 29.0% from ₹1,363 Cr in Q2 FY26 and up 31.6% from ₹735 Cr in Q1 FY27.
Promoters held 46.22% of Natco Pharma Ltd's shares as of Oct 2026, against 49.48% in Dec 2025 (−3.26 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.